振東製藥(300158.SZ):控股股東擬協議轉讓5%的股份予中泰資管計劃
格隆匯6月20日丨振東製藥(300158.SZ)公佈,公司控股股東山西振東健康產業集團有限公司(“振東集團”)與中泰證券(上海)資產管理有限公司(“中泰資管”)設立並管理的“證券行業支持民企發展系列之中泰資管計劃45號單一資產管理計劃”(“中泰資管計劃”)於2022年6月17日簽署《股份轉讓協議》,以協議轉讓的方式向中泰資管計劃轉讓公司5137.4735萬股股份,佔公司總股本的5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.